If this hypothesis is confirmed, it would suggest one mechanism by which obesity may contribute to the development of resistance to aromatase inhibitor therapy, a finding with potential clinical implications. Here, CYP19A1 is linked to obesity due to melanocortin 4 receptor deficiency.